CN105902852A - Pharmaceutical composition for treating psoriasis - Google Patents
Pharmaceutical composition for treating psoriasis Download PDFInfo
- Publication number
- CN105902852A CN105902852A CN201610322152.2A CN201610322152A CN105902852A CN 105902852 A CN105902852 A CN 105902852A CN 201610322152 A CN201610322152 A CN 201610322152A CN 105902852 A CN105902852 A CN 105902852A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- treatment
- treating psoriasis
- composition
- psoriasis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/483—Gleditsia (locust)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/51—Gentianaceae (Gentian family)
- A61K36/515—Gentiana
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Insects & Arthropods (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a pharmaceutical composition for treating psoriasis. The pharmaceutical composition is prepared from the following 25 raw medicine materials: abrus precatorius, honeycomb, semen hydnocarpi, Chinese honeylocust spine, lycoris radiate, semen arecae, cortex meliae, radix ampelopsis, herba artemisiae apiaceae, rhizoma menispermi, herba ajugae, halitum, common reed rhizome, radix gentianae and the like. by adding conventional auxiliary materials in the pharmaceutical composition disclosed by the invention according to a conventional technology, the pharmaceutical composition can be prepared into capsules, tablets, pills, granules, oral liquid, empladstrum, ointment, spray, liniment or tinctures which is clinically accepted; the pharmaceutical composition has the effects of clearing heat, promoting diuresis, dispelling wind and relieving itching; the effect in treating psoriasis is obvious, and no toxic and side effects are generated.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition, particularly relate to one and treat psoriatic pharmaceutical composition.
Background technology
Psoriasis is a kind of common chronic recurrent inflammatory dermatoses, and characteristic lesions is red papules or speckle overlying
Have multilamellar silvery white squama, be apt to occur in extremity and stretch side, scalp and back, serious skin lesion can general whole body, and may occur in which height
Heat, pustule, erythroderma sample change and whole body size arthropathy.The primary disease course of disease is long, the sustainable several years to many decades,
Period can recurrent exerbation.There is a not medication and spontaneous recovery person also has the medication person of increasing the weight of, also have and whole body erythroderma sample occurs because of medication
The patient of infringement.Psoriatic can have renal damage, also can be with organ diseases such as liver, eye, gastrointestinal tract, cardiovascular.
Pathogenesis not yet illustrates, it is now recognized that psoriasis is an immune-mediated genetic dermatosis.
Summary of the invention
Present invention aim at providing one to treat psoriatic pharmaceutical composition.
The present invention is achieved through the following technical solutions:
The crude drug of pharmaceutical composition of the present invention consists of:
The crude drug composition of pharmaceutical composition of the present invention is preferably:
The crude drug composition of pharmaceutical composition of the present invention is preferably:
The crude drug composition of pharmaceutical composition of the present invention is preferably:
Pharmaceutical composition of the present invention according to common process add customary adjuvant make the capsule of clinical acceptance, tablet, pill,
Granule, oral liquid, emplastrum, ointment, spray, liniment or tincture.
Pharmaceutical composition of the present invention has clearing away heat-damp and promoting diuresis, effect of dispelling wind for relieving itching.Notable to treatment psoriasis effect, nontoxic
Side effect.
Experimental example is used for further illustrating the present invention below, but is not limited to the present invention.
Experimental example one: clinical trial
1, clinical observation
Treatment group 1 anthology invention capsule (preparing according to embodiment 1 method) treatment psoriasis 100 example, wherein male 50
Example, women 50 example.
Treatment group 2 anthology invention ointment (preparing according to embodiment 2 method) treatment psoriasis 100 example, wherein male 50
Example, women 50 example.
Matched group selects painting capsule, Shanxi Kanghui Pharmaceutical Co., Ltd. produce, and treats psoriasis 100 example, wherein
Male 50 example, women 50 example.
2, medicament selection
Treatment group 1: capsule of the present invention (is prepared according to embodiment 1 method), treats three courses for the treatment of (5 days courses for the treatment of), mouth
Clothes, each serving 2, three times a day.
Treatment group 2: ointment of the present invention (is prepared according to embodiment 2 method), treats three courses for the treatment of (5 days courses for the treatment of), often
It is applied to affected part sooner or later.
Matched group: painting capsule, is produced by Shanxi Kanghui Pharmaceutical Co., Ltd., treats three courses for the treatment of (5 days courses for the treatment of),
Oral, each serving 4, three times a day, one after each meal.
3, diagnostic criteria
1. it is the inflammatory flat pimple that syringe needle is big during psoriasis onset.Being gradually increased and infiltrate speckle for coin pale red, boundary is clear
Chu, overlying multilamellar silvery white squama.Scraper surface squama gently, then thunderclap goes out one layer of shinny semitransparent thin film of pale red,
Claim film phenomenon.Strike off thin film again, then little petechia occurs, claim petechial hemorrhage phenomenon.
2. skin lesion can occur in any site symmetry of health.Be apt to occur in elbow, knee joint stretches side and head.A few patients
Refer to that (toe) first and mucosa also can be invaded.
3. the easy acute attack of psoriasis, chronic process, tendency recurrence.Morbidity is the most relevant with season.
4, criterion of therapeutical effect
" in cure the desease Standardization of diagnosis and curative effect " implemented with reference to State Administration of Traditional Chinese Medicine 1994 drafts as follows:
Recovery from illness: tcm clinical practice symptom, sign disappear or substantially disappear；
Effective: tcm clinical practice symptom, sign substantially change；
Effective: tcm clinical practice symptom, sign all take a favorable turn；
Invalid: tcm clinical practice symptom, sign are all not improved；
5, therapeutic outcome
Psoriatic Comparison of therapeutic treated by table 1
| Group | Effective (example) | Effectively (example) | Invalid (example) | Total effective (example) | Effective percentage |
| Treatment group 1 | 85 | 15 | 0 | 100 | 100% |
| Treatment group 2 | 89 | 11 | 0 | 100 | 100% |
| Matched group | 65 | 20 | 15 | 85 | 85% |
6, conclusion
Treatment group 1, treatment group 2 and matched group are treated three courses for the treatment of (5 days each courses for the treatment of) respectively, treatment group 1 and treatment
The effective percentage of group 2 is 100%, matched group effective percentage 85%.The effective percentage for the treatment of group 1 of the present invention and treatment group 2 is the most excellent
In matched group.
Experimental example two: model case
Case 1: Zhang, man, 51 years old, in more than 10 years of history of psoriasis, increases the weight of 5 years.This patient is accidental before more than 10 year
Find that desquamation, pruritus occurs in right ancon, do not give attention.Subsequently, bilateral ancon, lower back, scalp portion occur disease in succession
Become.Patient is once outer voluntarily in family is coated with the treatment of hormones liniment, has a certain curative effect, but recurrent exerbation, symptom is bright in recent years
Show and increase the weight of.Disease sees scalp thickness long-pending silver bits, and bilateral ancon, lower back skin is general to become damp red, accompanies a large amount of white plates desquamation,
Cortex is the thickest, and withered crowfoot cracks are with hemorrhage, and drier, convulsion is itched hard to bear, is afraid of cold, and diet is few, difference of sleeping night, once still can,
Dim red, the tongue root Huang of tongue, arteries and veins CHI-pulse being weak.Previously hypertension history 3 years, cerebral infarction medical history 1 year, diabetes medical history 1 year,
Deny there is Inheritance medical history.Diagnosis: psoriasis vulgaris.Take capsule of the present invention (preparing according to embodiment 1 method) 1
After the individual course for the treatment of (5 days per courses for the treatment of), it is thinning that hair thickness amasss squama, and whole body engenders the normal skin of lamellar, diffusivity tide
Red infiltration and long-pending reduce, desquamation minimizing degree is thin.After 2 courses for the treatment of of rear continual cure, skin depth without a head amasss squama, whole body
Skin recovers normal substantially, and flushing speckle significantly reduces, and color is light, the most normally, without desquamation, without itching over the body, and peace of sleeping night.
Follow up a case by regular visits to after half a year, satisfactory effect, do not recur.
Case 2: Lee, female, 60 years old.Lower limb distribute erythema more than ten years, cover squama, lesions position pachyderma.
Diagnosis: psoriasis (homeliness type), 2 course for the treatment of (per courses for the treatment of 5 of external ointment of the present invention (preparing according to embodiment 2 method)
My god) after, lower limb erythema reduces repairs, and continues to strengthen 1 course for the treatment of, and skin recovers normal substantially, and speckle significantly reduces, color
Light, the most normally, without desquamation, without itching over the body, peace of sleeping night.Follow up a case by regular visits to after half a year, satisfactory effect, do not recur.
Case 3: Guo, man, 43 years old.In more than 10 years of history of psoriasis, increase the weight of 4 years.This patient accidentally sent out before more than 10 year
There is desquamation, pruritus in existing left ancon.Subsequently, bilateral ancon, scalp portion occur pathological changes in succession.Patient once in family voluntarily
Outer painting hormones liniment is treated, and has a certain curative effect, but recurrent exerbation, symptom substantially increases the weight of in recent years.Disease sees that scalp thickness is amassed
Silver bits, bilateral ancon, lower back skin is general to become damp red, accompanies a large amount of white plates desquamation, and cortex is the thickest, withered crowfoot cracks companion
Having hemorrhage, convulsion is itched hard to bear, is afraid of cold, and diet is few, difference of sleeping night, dim red, the arteries and veins CHI-pulse being weak of tongue.Diagnosis: psoriasis vulgaris.
After taking 2 courses for the treatment of (5 days per courses for the treatment of) of Tablets (preparing according to embodiment 3 method), it is thinning that hair thickness amasss squama,
Whole body engenders the normal skin of lamellar, and diffusivity flushing infiltrates and long-pending reduction, and desquamation minimizing degree is thin.Rear continuation
After treating 1 course for the treatment of, recovery from illness.
Following embodiment all can realize the effect of above-mentioned experimental example.
Detailed description of the invention
Embodiment 1 capsule
Said medicine adds customary adjuvant according to common process and makes capsule, 0.5g/ grain, three times on the one, each 2.
Embodiment 2 ointment
Said medicine adds customary adjuvant according to common process and makes ointment.Every 10g, is applied to affected part twice every day sooner or later.
Embodiment 3 tablet
Said medicine adds customary adjuvant according to common process and makes tablet.Three times on the one, each 2.
Embodiment 4 spray
Said medicine adds customary adjuvant according to common process and makes spray.Every day is sprayed on affected part twice sooner or later.
Embodiment 5 granule
Said medicine adds customary adjuvant according to common process and makes granule.Every bag of 10g, daily three times, each 1
Bag.
Embodiment 6 liniment
Said medicine adds customary adjuvant according to common process and makes liniment.Every day wipes in affected part for twice sooner or later.
Claims (6)
1. treat psoriatic pharmaceutical composition for one kind, it is characterised in that the crude drug of said composition consists of:
2. pharmaceutical composition as claimed in claim 1, it is characterised in that the crude drug of said composition consists of:
3. pharmaceutical composition as claimed in claim 1, it is characterised in that the crude drug of said composition consists of:
4. pharmaceutical composition as claimed in claim 1, it is characterised in that the crude drug of said composition consists of:
5. the pharmaceutical composition as described in one of claim 1-4, it is characterised in that said composition adds according to common process
Customary adjuvant makes the capsule of clinical acceptance, tablet, pill, granule, oral liquid, emplastrum, ointment, spray
Mist agent, liniment or tincture.
6. the application in psoriatic medicine is treated in preparation of the pharmaceutical composition as described in one of claim 1-4.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610322152.2A CN105902852A (en) | 2016-05-10 | 2016-05-10 | Pharmaceutical composition for treating psoriasis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610322152.2A CN105902852A (en) | 2016-05-10 | 2016-05-10 | Pharmaceutical composition for treating psoriasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105902852A true CN105902852A (en) | 2016-08-31 |
Family
ID=56749110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610322152.2A Pending CN105902852A (en) | 2016-05-10 | 2016-05-10 | Pharmaceutical composition for treating psoriasis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105902852A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103070975A (en) * | 2013-02-20 | 2013-05-01 | 李超 | Traditional Chinese herbal medicine composition for treating psoriasis |
-
2016
- 2016-05-10 CN CN201610322152.2A patent/CN105902852A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103070975A (en) * | 2013-02-20 | 2013-05-01 | 李超 | Traditional Chinese herbal medicine composition for treating psoriasis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102579913A (en) | Traditional Chinese medicine composition for treating gouty arthritis | |
| CN1977899B (en) | Medicine for treating rheumatoid arthritis | |
| CN104971268A (en) | Nursing medicine for treating chronic eczema scroti and preparation method thereof | |
| CN102552520B (en) | Blood circulation-promoting and pain-stopping medicament and preparation process and application thereof | |
| CN102824576B (en) | Traditional Chinese medicinal composition for treating psoriasis and preparation method thereof | |
| CN101647943B (en) | Medicinal composition | |
| CN104056208A (en) | Medicament for treating penis induration and preparation method thereof | |
| CN103908600A (en) | Externally-applied medicine for treating rheumatoid arthritis damp-heat blockage symptom as well as preparation method and administration method thereof | |
| CN105902852A (en) | Pharmaceutical composition for treating psoriasis | |
| CN103405653A (en) | External preparation for treating gouty arthritis | |
| CN104248677A (en) | Traditional Chinese medicinal preparation for treating erythema multiforme | |
| CN115337373B (en) | Traditional Chinese medicine composition and medicine for treating cervical gastritis and preparation method thereof | |
| CN103263577B (en) | Medicine composition for treating psoriasis | |
| CN103211911A (en) | Medicine for treating thromboangiitis obliterans | |
| CN108096484A (en) | A kind of Chinese medicine composition and application for dissection of aorta peri-operation period | |
| CN102266539B (en) | Medicament for treating gastric ulcer | |
| CN101972317B (en) | Medicament for treating fallopian tube obstructive infertility | |
| CN104984166A (en) | Care medicine for treating eczema scroti and preparing method thereof | |
| Yuqiao et al. | Clinical Experience in Treating Eczema from the Perspective of Chinese Medicine | |
| CN104288511A (en) | Chinese medicinal suppository for treating internal hemorrhoid bleeding | |
| CN104138538A (en) | Medicine used for treating urticaria | |
| CN104147463B (en) | A kind of medicine for treating psoriasis | |
| CN103272072B (en) | Chinese medicinal composition for treating psoriasis | |
| CN101569728B (en) | Pharmaceutical composition for treating urticaria | |
| CN101385820B (en) | Traditional Chinese medicine composition containing ephedra for treating dermatomyositis and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160831 |
|
| RJ01 | Rejection of invention patent application after publication |